<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02273830</url>
  </required_header>
  <id_info>
    <org_study_id>20131001</org_study_id>
    <nct_id>NCT02273830</nct_id>
  </id_info>
  <brief_title>Benefits of Liquid Oxygen in COPD Patients Presenting Desaturation During Exercise.</brief_title>
  <official_title>Benefits of Liquid Oxygen in COPD Patients Presenting Desaturation on Exercise But Without Conventional Criteria for Domiciliary Oxygen Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jtarrega</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Mutua de Terrassa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Dos de Maig</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitari Sant Joan de Reus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital de Granollers</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is analyzed the impact of oxygen adjusted during exercise in COPD
      patients without conventional for LTOT but with exercise desaturation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oxygen will be administered through nasal cannulae. Patients will be provided with a tank of
      liquid oxygen and a rechargeable portable device. The 6 minuts walking test will be used to
      adjusted oxygen flow in the GFA group (to achieve a mean SpO2 ≥ 90%). In the control group
      (GC), a 3L/min oxygen flow will be administer. Oxygen is used when the patient perform
      physical activity. The treatment period for each patient is 6 months (3 months in the GC
      grup, 3 months in the GFA one).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Benefits on HRQOL</measure>
    <time_frame>3 months</time_frame>
    <description>The aim is to analyze the benefits on HRQOL of suitable correction of desaturation in COPD patients without conventional criteria for OCD but with exercise desaturation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduce breathlessness during exercise</measure>
    <time_frame>3 months</time_frame>
    <description>Reduce breathlessness during exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase exercise capacity</measure>
    <time_frame>3 months</time_frame>
    <description>Increase exercise capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increasing physical activity</measure>
    <time_frame>3 months</time_frame>
    <description>Increasing physical activity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>oxygen adjusted</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oxygen adjusted to get SpO2&gt; 90% during the walking test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oxygen at 3L/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxygen</intervention_name>
    <description>Oxygen administered after adjustment during a waking test or at 3L/min</description>
    <arm_group_label>oxygen adjusted</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical stable moderate to severe COPD (FEV1 &lt;70%, FEV 1 / FVC &lt;70%) total lung
             capacity (TLC&gt; 80%) without conventional criteria for LTOT, optimal medical therapy,
             mean SpO2 ≤ 88% during the 6 minuts walking test and active life outside the home,
             other than active smoking or are in program respiratory rehabilitation.

        Exclusion Criteria:

          -  Current smokers - Presence of respiratory failure and criteria for LTOT (PO2 &lt;55 mmHg
             or 55-60 mmHg associated with pulmonary arterial hypertension, chronic cor pulmonale,
             congestive heart failure, arrhythmias or polycythemia). - Presence of impaired
             mobility - Cognitive impairment or intellectual disability to fill in questionnaires -
             No acceptance of liquid oxygen - Presence of active comorbidities (cardiovascular
             disease, rheumatologic, renal, hepatic) - Participation in pulmonary rehabilitation
             programs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JULIA TARREGA, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital general de Granollers</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julia Tárrega, PhD</last_name>
    <phone>0034938425000</phone>
    <phone_ext>2675</phone_ext>
    <email>jtarrega@fhag.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital General de Granollers</name>
      <address>
        <city>Granollers</city>
        <state>BArcelona</state>
        <zip>08402</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Tarrega</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med. 1980 Sep;93(3):391-8.</citation>
    <PMID>6776858</PMID>
  </reference>
  <reference>
    <citation>Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet. 1981 Mar 28;1(8222):681-6.</citation>
    <PMID>6110912</PMID>
  </reference>
  <reference>
    <citation>Andersson A, Ström K, Brodin H, Alton M, Boman G, Jakobsson P, Lindberg A, Uddenfeldt M, Walter H, Levin LA. Domiciliary liquid oxygen versus concentrator treatment in chronic hypoxaemia: a cost-utility analysis. Eur Respir J. 1998 Dec;12(6):1284-9.</citation>
    <PMID>9877478</PMID>
  </reference>
  <reference>
    <citation>Bradley JM, Lasserson T, Elborn S, Macmahon J, O'neill B. A systematic review of randomized controlled trials examining the short-term benefit of ambulatory oxygen in COPD. Chest. 2007 Jan;131(1):278-85. Review.</citation>
    <PMID>17218587</PMID>
  </reference>
  <reference>
    <citation>Jolly EC, Di Boscio V, Aguirre L, Luna CM, Berensztein S, Gené RJ. Effects of supplemental oxygen during activity in patients with advanced COPD without severe resting hypoxemia. Chest. 2001 Aug;120(2):437-43.</citation>
    <PMID>11502641</PMID>
  </reference>
  <reference>
    <citation>Nonoyama ML, Brooks D, Guyatt GH, Goldstein RS. Effect of oxygen on health quality of life in patients with chronic obstructive pulmonary disease with transient exertional hypoxemia. Am J Respir Crit Care Med. 2007 Aug 15;176(4):343-9. Epub 2007 Apr 19.</citation>
    <PMID>17446339</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2014</study_first_submitted>
  <study_first_submitted_qc>October 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2014</study_first_posted>
  <last_update_submitted>February 28, 2017</last_update_submitted>
  <last_update_submitted_qc>February 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Granollers</investigator_affiliation>
    <investigator_full_name>Jtarrega</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>oxygen therapy</keyword>
  <keyword>COPD</keyword>
  <keyword>exercise</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

